Comparison of radiation therapy alone and concurrent chemoradiation therapy in stage III cervical cancer: a multicenter retrospective study.
OBJECTIVE
To evaluate whether concurrent chemoradiation therapy (CRT) improves overall survival as compared to radiation therapy (RT) alone in stage III cervical cancers.


METHODS
A multicenter retrospective review.


METHODS
Nine tertiary medical centers in Korea.


METHODS
A total of 277 patients treated for stage III cervical cancer without para-aortic lymph node (PALN) metastasis based on clinical staging workup from 1996 to 2003.


METHODS
Medical and histopathological record review.


METHODS
Disease-specific overall survival.


RESULTS
CRT and RT alone were performed in 172 and 105 patients, respectively. There was no significant difference in disease-specific overall survival between the CRT and RT alone arms based on clinical staging workup, even though the CRT arm was characterized by younger age, more favorable performance status and lower pretreatment blood urea nitrogen level as compared to the RT alone arm. In the CRT arm, three patients succumbed to treatment-related death.


CONCLUSIONS
CRT does not improve the overall survival rate in stage III cervical cancer as compared to RT alone based on clinical staging workup for PALN status. Special care needs to be taken regarding optimal dose and duration of RT, use of brachytherapy, anemia control and accurate pretreatment staging workup to improve survival outcome in patients with stage III cervical cancer.
Lee
Jong-Min
JM
Department of Obstetrics and Gynecology, East-West Neo Medical Center, Kyung Hee University, Seoul, Korea.
Tong
Seo-Yun
SY
Lee
Kwang-Beom
KB
Kim
Young-Tae
YT
Kim
Young-Jae
YJ
Kim
Jae Weon
JW
Kim
Seok-Mo
SM
Cho
Chi-Heum
CH
Kim
Ki-Tae
KT
Cho
Young-Lae
YL
Lee
Kyu-Chan
KC
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007723:Korea; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents